Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (376)	2/11/2000 9:39:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

Dear Mr. L.S.Schelifer, With all due respect, but seams to me that You are one pain in the ... type guy. Does we shareholders deserve to hear bit about Company and what is going on? Status of the NT-3 and BDNF clinical trials and what are time-frame and plans about this candidates? That Company is spending more on this trials is nothing new. Bios always spent more than they should. <g> Full results from Axokine PI trial and program for PII? Where are now Axokine-2? In last Q-report and at RS conference Company and You disclosed some excelent results on cytokine traps technology and intention/plan to partner this (with human trial for one candidate to start in 2000). How long it take to complete this? Until patents expire or consumers get tired from similar drug on market? There is many more questions, but this will do it for now. In my account (and my patience is running very thin) Company have until Feb-end to do something. You are, or You are not? There are no more excuses for failure to delivery. Miljenko PS: Maybe Lubetkin did run out of patience???